DrugPatentWatch Database Preview
TECHNIVIE Drug Profile
» See Plans and Pricing
When do Technivie patents expire, and when can generic versions of Technivie launch?
Technivie is a drug marketed by Abbvie Inc and is included in one NDA. There are ten patents protecting this drug.
This drug has four hundred and forty-two patent family members in forty-seven countries.
The generic ingredient in TECHNIVIE is ombitasvir; paritaprevir; ritonavir. Additional details are available on the ombitasvir; paritaprevir; ritonavir profile page.
US ANDA Litigation and Generic Entry Outlook for Technivie
Technivie was eligible for patent challenges on December 19, 2018.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be April 13, 2032. This may change due to patent challenges or generic licensing.
There have been twelve patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.
Indicators of Generic Entry
Summary for TECHNIVIE
| International Patents: | 442 |
| US Patents: | 10 |
| Applicants: | 1 |
| NDAs: | 1 |
| Bulk Api Vendors: | 1 |
| Clinical Trials: | 2 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for TECHNIVIE |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for TECHNIVIE |
| DailyMed Link: | TECHNIVIE at DailyMed |
Generic Entry Opportunity Date for TECHNIVIE
Generic Entry Date for TECHNIVIE*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for TECHNIVIE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| AbbVie | Phase 3 |
US Patents and Regulatory Information for TECHNIVIE
Expired US Patents for TECHNIVIE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Abbvie Inc | TECHNIVIE | ombitasvir; paritaprevir; ritonavir | TABLET;ORAL | 207931-001 | Jul 24, 2015 | Start Trial | Start Trial |
| Abbvie Inc | TECHNIVIE | ombitasvir; paritaprevir; ritonavir | TABLET;ORAL | 207931-001 | Jul 24, 2015 | Start Trial | Start Trial |
| Abbvie Inc | TECHNIVIE | ombitasvir; paritaprevir; ritonavir | TABLET;ORAL | 207931-001 | Jul 24, 2015 | Start Trial | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for TECHNIVIE
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Denmark | 2206500 | Start Trial |
| Spain | 2414934 | Start Trial |
| Japan | 5087409 | Start Trial |
| Mexico | 2013009763 | Start Trial |
| South Korea | 101586215 | Start Trial |
| Argentina | 077411 | Start Trial |
| Eurasian Patent Organization | 020031 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for TECHNIVIE
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2692346 | 2017/046 | Ireland | Start Trial | PRODUCT NAME: PIBRENTASVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF.; REGISTRATION NO/DATE: EU/1/17/1213 20170726 |
| 2692346 | PA2017033 | Lithuania | Start Trial | PRODUCT NAME: PIBRENTASVIRAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/17/1213 20170726 |
| 2692346 | C02692346/01 | Switzerland | Start Trial | PRODUCT NAME: PIBRENTASVIR; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66472 22.09.2017 |
| 2340029 | C 2015 019 | Romania | Start Trial | PRODUCT NAME: PARITAPREVIR; NATIONAL AUTHORISATION NUMBER: EU/1/14/982; DATE OF NATIONAL AUTHORISATION: 20150115; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/14/982; DATE OF FIRST AUTHORISATION IN EEA: 20150115 |
| 2340029 | 132016000021931 | Italy | Start Trial | PRODUCT NAME: PARITAPREVIR IN TUTTE LE FORME PROTETTE DAL BREVETTO DI BASE(VIEKIRAX); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/14/982/001, 20150119 |
| 2340029 | 122015000042 | Germany | Start Trial | PRODUCT NAME: PARITAPREVIR; REGISTRATION NO/DATE: EU/1/14/982 20150115 |
| 2340029 | C02340029/01 | Switzerland | Start Trial | PRODUCT NAME: PARITAPREVIR; REGISTRATION NO/DATE: SWISSMEDIC 65301 25.11.2014 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
